FDA Seeks Risk-Based Inspection Program

FDA's new policies intend to make GMP inspections more efficient and apply to stricter rules to high-risk products and processes.

Related Content:

Regulatory Oversight and CompliancePharmaceutical Technology-11-02-2003

FDA Posts Slate of Seven Warning Letters Following Company Inspections

FDA Approves New Moderna COVID-19 Vaccine mNEXSPIKE

Geopolitical Shifts Change Nature of Pharma Partnerships